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BACKGROUND Early subcutaneous implantable cardioverterdeﬁbrillator (S-ICD) studies included atypical cohorts of patients
who were younger with fewer comorbidities. Recent S-ICD studies
included patient populations with more comorbidities.
OBJECTIVES The goals of this study were to determine the incidence and predictors of S-ICD–related infection over a 3-year
follow-up period and to use these results to develop an infection
risk score.
METHODS The S-ICD Post Approval Study is a US prospective registry of 1637 patients. Baseline demographic characteristics and outcomes with 3-year postimplantation follow-up were compared
between patients with and without device-related infection. A
risk score was derived from multivariable proportional hazards analysis of 22 variables.
RESULTS Infection was observed in 55 patients (3.3%), with 69%
of infections occurring within 90 days and a vast majority (92.7%)
within 1 year of implantation. Late infections more likely involved
device erosion; no infections occurred after year 2. The annual mor-

tality rate postinfection was 0.6%/y. No lead extraction complications or bacteremia related to infection were observed. An
infection risk score was created with diabetes, age, prior transvenous ICD implant, and ejection fraction as predictors. Patients
with a risk score of 3 had an 8.8 hazard ratio (95% conﬁdence interval 2.8–16.3) of infection compared with a 0 risk score.
CONCLUSION Infection rates in the S-ICD Post Approval Study
were similar to other S-ICD populations and not associated with systemic blood-borne infections. Late infection (.1 year) is uncommon and associated with system erosion. A high-risk infection
cohort can be identiﬁed that may facilitate preventive measures.
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Introduction
The subcutaneous implantable cardioverter-deﬁbrillator (SICD) is available worldwide for the prevention of sudden cardiac death, with .100,000 devices implanted.1 The S-ICD
has no intravascular components and has demonstrated safety
and efﬁcacy for treating ventricular tachyarrhythmias.2–6
One of the primary advantages of this device is to
minimize the risk of lead complications including systemic
infections. Early studies showed a low lead failure rate
compared to transvenous devices. Although infections still
occur at similar rates, bacteremia did not occur.4–9 Oneyear transvenous ICD (TV-ICD) infection rates have ranged
from 0.5% to 1.2%.10–12 Despite the well-studied predictors
of TV-ICD infections,11–16 no such analysis has been
performed for the S-ICD.
Although previous studies validated the efﬁcacy and
safety of S-ICD, the patient population was often atypical
for ICD cohorts, with subjects being younger with fewer comorbidities.2,4,5,8,9 Moreover, follow-up durations were
often short. The more recent S-ICD Post Approval Study
(S-ICD PAS),7,17 Prospective, RAndomizEd comparison of
subcuTaneOus and tRansvenous ImplANtable cardioverterdeﬁbrillator therapy (PRAETORIAN),6 and UNdersTanding
OUtcomes With the S-ICD in Primary Prevention Patients
With Low Ejection Fraction3,18 trials are more typical of
traditional ICD cohorts and thus represent more relevant populations to assess efﬁcacy and risks. In this regard, S-ICD
PAS was a prospective US registry of this device, with
long-term follow-up prospectively planned.7,17 The present
report is an analysis of infections during the ﬁrst 3 years of
this trial, with a risk score to help identify a high-risk cohort
to inform patient management decisions including infection
preventive measures.

Methods
S-ICD PAS is a prospective registry with 1637 de novo patients enrolled across 86 US centers (ClincalTrials.gov Identiﬁer NCT01736618), which was mandated by the Food and
Drug Administration after device approval. Enrollment demographic details were published previously.17 The protocol
was approved by local institutional review boards before use.
The study was conducted in accordance with applicable postmarket guidelines and the Declaration of Helsinki as revised
in 2013. Patients eligible for S-ICD underwent a manual electrocardiogram screening test and underwent implantation
from August 2013 until May 2016. Data up to 3 years postimplantation were used for this analysis.
Complications were deﬁned as adverse events related to
the implant procedure or the device, resulting in permanent
loss of device function, invasive intervention, or death. All
complications were veriﬁed by an independent clinical
events committee. Any patient whose S-ICD was removed
and not replaced with another S-ICD was removed from
the study at the time of explantation. For this analysis, patients were stratiﬁed into 2 groups: those who had an infec-

tion complication or those with no infection complication.
Patients with erosion complications were evaluated to determine whether infections were also involved as the root cause
is often uncertain (infection or erosion). Accordingly, if
concomitant infections were present with erosion, then patients with those infections were included into the infection
complication group. Patients were censored at study discontinuation date to evaluate repeat infection occurrence. Patient
mortality was assessed in (1) patients with a previous TVICD extracted owing to infection and (2) patients with infection.

Statistical analysis
Basic characteristics were analyzed using descriptive statistics. Kaplan-Meier analysis was performed by censoring subjects at their last known status. Proportional hazards analysis
was used to calculate hazard ratios (HRs), 95% conﬁdence
intervals, and Wald c2 P values. For proportional hazards
analysis, all variables of interest were entered into the model,
followed by stepwise selection criteria with a P value of .2 to
enter the model and .2 to remain in the model.
An infection risk score model was developed on the basis
of the multivariable predictors, excluding predictors with
.5% missing values. Backward model selection was performed with a 5 5% using a proportional hazards model.
Risk score development was performed with 1000 bootstrap
data sets (see Online Supplemental Figure 1). The bootstrapping method was used to avoid data overﬁtting in risk model
development.19 Subjects not selected for a given bootstrap
development data set were used for risk score validation.
On average, the development set included 65% of patients,
with the validation set including the remaining 35%. Logistic
regression was performed on continuous variables and
receiver operating characteristic curve analysis was used to
identify the optimal threshold point across all bootstrap samples. A multivariable proportional hazards model was run using the bootstrap samples and resulting threshold points to
ﬁnd the median variable b for each predictor. Integer risk
scores were assigned on the basis of b variables. Risk scores
were combined for small patient cohorts.
All statistical analyses were performed using SAS version
9.4 (SAS Institute, Cary, NC). A P value of ,.05 was considered statistically signiﬁcant.

Results
Within 3 years of implantation, 55 patients (3.4%) had an
infection. There were no reported deaths attributed to infection or subsequent S-ICD pulse generator (PG) and/or electrode removal. No patient had .1 infection. Of the 55
patients with an infection, 45 (81.8%) had S-ICD system–
related infections with the PG explanted in all cases, 4
(7.3%) patients had an infection classiﬁed as superﬁcial
infection involving intervention but no device removal, and
6 (10.9%) remaining patients had an infection associated
with electrode or PG erosion. For these 6 patients, the PG
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Subject demographic characteristics and procedural outcomes

Characteristic
Age (y)
Mean 6 SD (median)
Range
Male
Body mass index (kg/m2)
N
Mean 6 SD (median)
Range
Primary prevention
LVEF (%)
N
Mean 6 SD (median)
Range
NYHA HF class III–IV
Diabetes
Prior TV-ICD implant
Prior TV-ICD implant, explanted owing to
infection
Dialysis
Oral anticoagulant
Procedure time (min)
N
Mean 6 SD (median)
Range
Length of stay (d)
N
Mean 6 SD (median)
Range
Inpatient procedure
Prophylactic antibiotics given
PG implanted in the subcutaneous
location
2 Incision implantation method
General anesthesia
Conscious sedation
Local anesthesia
Hematoma
Experience variables
IDE center
Implant number
N
Mean 6 SD (median)
Range
Implant tertile
1
2
3
Implant year
2013
2014
2015
2016

Infection (n 5 55[3.4%])

No infection(n 5 1582 [96.6%])

51 6 14(51)
19–80
36/55(65.5)

53 6 15(55)
15–89
1086/1582(68.6)

55
32 6 8 (31)
16–53
42/55 (76.4)

1578
30 6 8 (28)
9–101
1212/1582 (76.6)

55
29 6 14(27)
5–65
15/47(31.9)
27/55(49.1)
20/55(36.4)
14/55(25.5)

1538
32 6 15(30)
5–85
382/1349(28.3)
524/1582(33.1)
191/1582(12.1)
97/1582(6.1)

7/55(12.7)
15/55(27.3)

213/1582(13.5)
412/1582(26.0)

P
.27
.62
.03

.97
.12

.59
.01
,.0001
,.0001†
.87
.84
.03

55
88 6 40(82)
25–199

1560
77 6 36(69)
2–280

55
3 6 5(1)
0–28
8/55(14.5)
53/54(98.1)
52/55(94.5)

1582
3 6 6(1)
0–73
304/1582(19.2)
1516/1551 (97.7)
138/1579 (91.3)

28/54 (51.9)
34/55 (61.8)
21/55 (38.2)
0/55 (0.0)
4/55 (7.3)

825/1581 (52.2)
1015/1581 (64.2)
564/1581 (35.7)
2/1581 (0.1)
29/1582 (1.8)

.96
.72

23/55 (41.8)

666/1582 (42.1)

.97
.12

55
15 6 15 (12)
1–73

.67‡

.39
1.00
.62

.02

1582
17 6 15 (13)
1–86
.53

23/55 (41.8)
18/55 (32.7)
14/55 (25.5)

570/1582 (36.0)
503/1582 (31.8)
509/1582 (32.2)

4/55 (7.3)
13/55 (23.6)
25/55 (45.5)
13/55 (23.6)

80/1582 (5.1)
366/1582 (23.1)
782/1582 (49.4)
354/1582 (22.4)

.87

Values are presented as n/total n (%) unless otherwise indicated.
HF 5 heart failure; IDE 5 investigational device exemption; LVEF 5 left ventricular ejection fraction; NYHA 5 New York Heart Association; PG 5 pulse generator; TV-ICD 5 transvenous implantable cardioverter-deﬁbrillator.
†
P value calculated using the Fisher exact test.
‡
P value calculated using the Kruskal-Wallis test.

was explanted in 5 (9.1%) patients. In the sixth patient, electrode erosion occurred with the lead removed while the PG
remained implanted. Thus, of the 55 patients who had an

infection, 50 (90.9%) had their PG explanted (Online
Supplemental Table 1) and 2 of these (3.6%) had an S-ICD
replacement.
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Figure 1

A: Kaplan-Meier analysis of infections. B: Infection date postimplantation by infection type. PG 5 pulse generator.

Baseline demographic and procedural
characteristics
Baseline demographic and procedural characteristic comparisons are presented in Table 1. Patients with infection were
younger, had a higher body mass index, and were more likely
to have diabetes (P 5 .01). Importantly, severity of heart failure, dialysis, and oral anticoagulation use did not affect infection risk.
From a procedural perspective, prior transvenous deﬁbrillator implant (P , .0001) was associated with infection.
Longer procedure time and hematoma complicating implant

surgery were also associated with infection. Patients with
a prior TV-ICD explanted because of infection leading to
S-ICD implantation did not have a higher mortality rate
than did the rest of the study cohort (12.6% [14 of 111] vs
11.1% [170 of 1526]; P 5 .64).
Because of the observational nature of S-ICD PAS, evaluation of systemic infection and documentation of culture results and antibiotic treatment were not required and thus not
routinely collected, so these results should be interpreted with
caution. In the 18 patients for whom culture results (wound or
unspeciﬁed) were recorded, most infections were due to
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A
Infection Risk

Variable

Hazard Ratio

Procedure Time (mins)*
2 Incision
Oral Anticoagulant
Diabetes
Body Mass Index (kg/m^2)*
Age at Implant (years)*
Primary Prevention Indication
Length of stay (days)*
Hematoma prior to infection
General Anesthesia
Conscious Anesthesia
Dialysis
In Patient
Prior TV-ICD
Prior TV-ICD extracted due to infection
IDE Center †
Implant Number* †
Tertile of Implant Order* †
Implant Year* †
Race - White
NYHA Class III or IV
LVEF*

1.01 (1.00-1.01)
0.99 (0.58-1.69)
1.09 (0.60-1.98)
1.96 (1.16-3.33)
1.03 (1.01-1.06)
0.99 (0.97-1.01)
0.97 (0.52-1.80)
1.00 (0.95-1.05)
4.23 (1.53-11.71)
0.91 (0.53-1.57)
1.11 (0.64-1.91)
0.98 (0.44-2.16)
0.70 (0.33-1.49)
4.03 (2.33-6.98)
5.01 (2.73-9.19)
0.99 (0.58-1.69)
0.99 (0.97-1.01)
0.83 (0.60-1.15)
0.94 (0.68-1.30)
0.74 (0.43-1.25)
1.23 (0.67-2.27)
0.98 (0.96-1.00)
0.01

P-value
.028
.97
.77
.013
.019
.28
.92
.88
.0055
.73
.71
.95
.36
<.0001
<.0001
.97
.27
.25
.71
.25
.51
.12

0.1

1

10

100

Less Risk More Risk

B
Infection Risk

Variable

Hazard Ratio

Diabetes
Age at Implant (years)*
Prior TV-ICD
LVEF*

1.905 (1.096-3.308)
0.978 (0.959-0.997)
4.836 (2.766-8.453)
0.978 (0.958-0.999)

P-value
.022
.021
<.0001
.038

0.01

1

100

Less Risk More Risk
Figure 2 A: Univariable predictors of infection. B: Multivariable predictors of infection. IDE 5 investigational device exemption; LVEF 5 left ventricular
ejection fraction; NYHA 5 New York Heart Association; TV-ICD 5 transvenous implantable cardioverter-deﬁbrillator. * continuous variable; † variables to
evaluate implant experience.

Staphylococcus species (Online Supplemental Table 2), with
66.7% of patients showing either unspeciﬁed Staphylococcus
(6 of 18 [33.3%]), methicillin-resistant S aureus (5 of 18
[27.8%]), or methicillin-sensitive S aureus (1 of 18
[5.6%]). Only 2 of 18 patients (11.1%) had documented
blood culture results, who both showed no bacteremia. Of
the 55 patients who had an infection, 1 patient died (1.8%).
In contrast, the noninfection cohort had 11.2% deaths
(183 of 1582), which was a signiﬁcantly higher death rate
(P 5 .024). The 1 patient in the infection cohort who died
had a history of heart failure (New York Heart Association
class III/IV) and kidney failure. Fifteen days postimplanta-

tion, the patient’s device was explanted because of a recurring hematoma and infection; the latter was conﬁrmed by
wound culture results. The patient chose comfort care and
died 28 days after device implant, with the cause of death reported as worsening heart and kidney failure.

Incidence and timing
Kaplan-Meier analysis of infection complication occurrence
over 3 years after S-ICD implantation is shown in Figure 1A.
Most infections occurred within the ﬁrst 180 days (47 of 55
[85.4%]). Of the remaining 8 (14.5%) infections, 4 (7.3%)
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Table 2 Median b values from proportional hazards model and
resulting risk scores for each predictor
Predictor

Median b values

Components of the
risk score

Diabetes
Age  55 y
Previous ICD implant
LVEF  30%

0.64
0.70
1.59
0.75

1
1
2
1

ICD 5 implantable cardioverter-deﬁbrillator; LVEF 5 left ventricular
ejection fraction.

occurred within the ﬁrst year of implant and the remaining 4
(7.3%) occurred between years 1 and 2. No infections were
reported between years 2 and 3. The 4 infections without device removal and not associated with erosion occurred within
125 days of implantation. All 45 (81.8%) infections requiring
device removal that did not involve erosion occurred within
the ﬁrst year of implant. The 3 (5.5%) infections involving
lead erosion occurred 124, 331, and 372 days postimplantation, whereas the 3 (5.5%) infections involving PG erosion
occurred between year 1 and year 2 postimplantation
(Figure 1B).

Infection predictors
Multivariable proportional hazards analysis was performed
to evaluate patient- and procedure-related characteristics
associated with S-ICD-related infection over 3 years. Univariable and multivariable logistic regression analysis results
are shown in Figures 2A and 2B, respectively. None of the
indicators of implantation experience (investigational device
exemption center, implant number, implant order tertile, and
implant year) were signiﬁcant univariable or multivariable
predictors of S-ICD-related infection. Signiﬁcant multivariable infection predictors were diabetes (HR 1.91; P 5
.022), younger age (HR 0.98; P 5 .021), prior TV-ICD
implant (HR 4.84; P , .0001), and lower left ventricular
ejection fraction (LVEF) (HR 0.98; P 5 .038). It is noteworthy that although dialysis was included in the model,
on the basis of previous studies indicating it as a risk factor
for cardiovascular implantable electronic device infections,12,13 it was not a signiﬁcant independent predictor of
S-ICD-related infection.
A risk factor model was developed on the basis of the
multivariable infection predictors and identiﬁed their risk
score coefﬁcients (Table 2). The distribution of risk scores
for 1593 of 1637 patients (97.3%) in the S-ICD PAS study
is illustrated in Figure 3A. Risk scores 3–5 were combined
as they represented only 18.9% of patients. Kaplan-Meier
estimates by risk scores are presented in Figure 3B for all
S-ICD PAS patients. The 3-year Kaplan-Meier estimates
for the test data set, the validation data set, and the entire
cohort were similar (Online Supplemental Figure 2).
Figure 3C illustrates the HRs and 95% conﬁdence intervals
for risk scores 1, 2, and 3–5, compared with a risk score
of 0. For all data sets, the 95% conﬁdence intervals for risk

scores 1 and 2 span unity whereas the HR for risk scores
 3 was 8.8.

Discussion
The present study used the largest S-ICD prospective study to
date. While infection was not the primary end point of S-ICD
PAS, the registry allowed assessment of risk. Moreover, this
is the ﬁrst report to evaluate clinical predictors of S-ICDrelated infection. We evaluated the incidence of all infections
reported as complications (requiring invasive intervention),
including superﬁcial infections and infections associated
with erosions.15,16 This broad criteria for inclusion was chosen to prevent underestimating infection risk and to report on
infection complications that may not require S-ICD extraction.
We report several important ﬁndings. First, infection
occurred in 3.3% of patients (55), with the vast majority
occurring in the ﬁrst year postimplantation. Furthermore,
no patient had .1 infection during 3-year follow-up. Second,
all infections occurring after the ﬁrst year postimplantation
were associated with lead or PG erosion. Moreover, no patient had an infection after the second year postimplantation.
Third, implantation duration, hematoma, and system revision
were all univariable predictors of infection, similar to predictors from TV-ICD studies.12,16,20,21 However, dialysis was
not a predictor for infection, presumably because transient
bacteremia is unlikely to contaminate the S-ICD system.
Fourth, a risk score was developed to predict infection that
was strongly predictive of events. Speciﬁcally, a risk score
of 3 (range 0–5) was associated with 8.8 times increased
infection risk vs a risk score of 0.
Infection incidence has been evaluated in other S-ICD patient cohorts. In the investigational device exemption study,
the infection rate requiring explanation was 1.2% at followup of w1 year.5 In the Dutch cohort it was 5.1% at 1
year,4 whereas in the Evaluation oF FactORs ImpacTing
CLinical Outcome and Cost EffectiveneSS of the S-ICD registry it was 2.3%.2 Thus, the 3.2% 1-year infection rate (2.7%
for infections requiring device explantation) in the present
study is within the range noted previously, despite a cohort
with more comorbidities including heart failure, cardiomyopathy, and diabetes. In support of this ﬁnding, the UNdersTanding OUtcomes With the S-ICD in Primary Prevention
Patients With Low Ejection Fraction study of primary prevention patients with a reduced ejection fraction reported
an infection rate of 1.1% in 18 months with device explantation and an overall infection rate of 1.5% in 18 months.3 The
PRAETORIAN trial reported a low annual (0.2%) infection
rate with only 4 (0.9%) infections over 48 months in the SICD cohort (n 5 426).6 Thus, the more contemporary cohorts
of sicker and somewhat older patients were not associated
with an increased infection risk. This may be due to improved
implantation techniques, smaller devices, or more experienced implanters.
This study identiﬁed 4 risk factors of S-ICD-related infection: patients with a previous ICD implant (extracted for any
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Figure 3 A: Risk score distribution for patients in the S-ICD Post Approval Study; 44 patients had missing information for 1 predictors. B: Kaplan-Meier
estimates by risk score. C: Hazard ratios for each risk score across the entire population.

reason), age  55 years, LVEF  30%, and patients with diabetes. Patients with a risk score of 3 have an infection risk
8.8 times higher than patients with a risk score of 0. Similarly,
TV-ICD infection risk models showed that prior transvenous
device replacement/revision/upgrade procedures increase
infection risk.11,13,21 In contrast, 1 study showed that SICD recipients with a previous TV-ICD did not have an
increased infection risk.22 The present study includes sicker
patients and longer follow-up, which could explain this
discrepancy. Younger age was found to be a risk factor in
2 transvenous device infection studies,11,12,23 with
previously speculated reasons being changes in immune
response and subcutaneous tissue ﬁrmness that occur with
age.11,23 Whereas LVEF was not part of TV-ICD infection
Table 3

risk models, heart failure was included in 3 studies11,13,21
but prevailed in the risk model in only 1 study.13 Presumably,
heart failure or low LVEF did not prevail in other risk
models, as they covary with other variables such as type of
device implant and number of previous procedures. Diabetes
was also included in TV-ICD infection risk models.11–13,21
The present report describes infection incidence from implantation years 2013–2016, which is relatively early in the SICD experience. However, it is noteworthy that no implant experience variables were associated with infection (Figure 2A).
Several studies have compared S-ICD- and TV-ICDrelated infection rates,24–30 including 2 prospective
randomized studies.6,31 The PRAETORIAN trial showed
0.9% S-ICD-related infection compared with 1.9% TV-

S-ICD- and TV-ICD-related infection rates, year 1 and after year 1

First author, year,
reference
27

Brouwer et al (2016)

Palmisano et al (2021)26
Boersma et al (2017)2
Quast et al (2018)4

Study/type

Device
type(s) % SC

Follow-up
No. of duration
patients (y)

Overall
Infection Infections per
infection rate at
year after
rate (%) year 1 (%) year 1 (%)

Netherlands 2 high-volume
centers; propensity matched
POINTED registry; propensity
matched
EFFORLTESS S-ICD registry
Dutch Cohort S-ICD registry

S-ICD
TV-ICD
S-ICD
TV-ICD
S-ICD
S-ICD

140
140
169
169
984
118

4.10
3.60
0.60
1.20
2.30
6.80

N/A
11.40
N/A
81.70
N/A
N/A

5
5
2.5
2.5
3
6.1

3.00
0.00
0.60
0.60
2.3
5.1

0.28
0.9
0.00
0.40
0.00
0.33

EFFORLTESS 5 Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD; N/A 5 not available; POINTED 5 Impact on Patient
Outcome of Cardiac ImplaNTable Electronic Device Complications; SC 5 single chamber; S-ICD 5 subcutaneous implantable cardioverter-deﬁbrillator; TV-ICD 5
transvenous implantable cardioverter-deﬁbrillator.
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Figure 4 S-ICD-related infection rates per year, ﬁrst year postimplantation vs subsequent years. Note: this graph plots the S-ICD data in Table 3 columns
“Infection rate year 1 (%)” and “Infections per year after year 1 (%). EFFORTLESS 5 Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD; POINTED 5 Impact on Patient Outcome of Cardiac ImplaNTable Electronic Device Complications; S-ICD 5 subcutaneous implantable
cardioverter-deﬁbrillator.

ICD-related infection at 4-year follow-up.6 Recently, the
Avoid Transvenous Leads in Appropriate Subjects trial reported 2 S-ICD-related infections (0.8%) compared with 1
TV-ICD-related infection (0.4%) at 6-month follow-up.31
No study to date has shown a signiﬁcant difference in
device-related infection between patients with S-ICD and
those with TV-ICD.
Table 3 summarizes S-ICD-related infection rates from
studies reporting infections beyond 1 year, including 2
studies with S-ICD and TV-ICD propensity score–matched
data. S-ICD-related infection rates are also shown graphically
in Figure 4. The annual S-ICD infection rates after year 1 are
considerably lower than rates at year 1; indeed, 2 studies reported 0 infections after year 1.2,26 Infection rates after 1 year
implantation appear considerably lower in patients implanted
with the S-ICD than in those with TV-ICD, presumably
because of the markedly decreased risk of blood-borne infections.
Infection rates were signiﬁcantly decreased with an antibacterial envelope in transvenous device implantation.10,32
While antibacterial envelope use has been recommended
for transvenous device recipients at high infection risk,33 it
is unknown whether such measures would signiﬁcantly
impact S-ICD-related infection risk. Nevertheless, it is recommended that high-risk patients identiﬁed in this risk model
be considered for such preventive measures.
Although overall infection rates may have no signiﬁcant
differences between device types, the consequences may be
more severe with the TV-ICD, especially when undergoing
transvenous replacements.22,34 After TV-ICD explantation,
S-ICD implantation mortality risk appears lower than that
for TV-ICD reimplantaton. Boersma et al22 reported a
3.6% mortality rate over 3 years post TV-ICD extraction
for infection when an S-ICD has been reimplanted. The present study demonstrated no mortality difference between patients with a previous TV-ICD explant for infection
compared with the rest of the S-ICD cohort. Indeed, the mortality rate of S-ICD PAS patients with an S-ICD-related
infection was 0.6%/y, which was signiﬁcantly lower than

the mortality rate of 3.7%/y for noninfection S-ICD PAS patients. This low mortality after S-ICD reimplantation after device infection constrasts with TV-ICD reimplantation. A
large single-center study reported a 10% mortality for pocket
infections and a 32% mortality for endocarditis-related cardiovascular implantable electronic device infections over 3
years postextraction.34 These studies showing outcomes
managing TV-ICD infections with an S-ICD reimplantation
are compelling, suggesting that such an approach should be
considered for managing TV-ICD infections.
This study should be interpreted in light of certain limitations. S-ICD PAS was not speciﬁcally focused on infection
rates. Thus, some parameters that might be signiﬁcant predictors of infection were not collected. Second, microbiological
data were not systematically collected and are incomplete.
However, the data obtained showed that gram-positive organisms, particularly Staphylococcus species, were the dominant bacteria associated with infection, as expected. In
addition, there was no predetermined treatment algorithm
for infection; thus, this study represents a real-world experience vs a systematic approach to infection management.
Furthermore, the risk score has not been externally validated.
Finally, a variety of implantation techniques are used for SICD implants, so it is unclear which procedural aspects of implantation may have contributed to higher infection rates.

Conclusion
During 3 years of follow-up of S-ICD PAS, 3.3% of patients
had a device infection, no patient had recurring infections, no
patient had bacteremia, and patients who had a device infection did not have a higher mortality rate. An infection risk
score was created for patients implanted with the S-ICD; patients with a risk score of 3 are 8.8 times as likely to have an
infection as those with no comorbidities affecting infection:
diabetes comorbidity, age . 55 years, previous ICD implant,
and LVEF . 30%. Identifying high-risk subgroups may help
to develop preventive strategies to reduce further infection
with this device, such as antibiotics with a longer half-life
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or an antibacterial envelope. S-ICD implantation after TVICD infection is a viable approach that may be preferable
to implanting another transvenous device.
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